EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients
Executive Summary
EU approval of Tecentriq and Avastin together with chemo for the first-line treatment of metastatic non-squamous NSCLC is a positive advance for Roche, but analysts say the combo has a long way to go still to catch up with Merck & Co’s Keytruda combination.
You may also be interested in...
France OKs Early Access To Tecentriq For SCLC Pending EU Approval
Tecentriq has become the second authorized medicine to be made available for an unapproved indication under modifications to France’s early access program. Patients with small cell lung cancer can now be given the product pending EU approval of its use in this condition.
Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin
Unique NDCs, Medicare reimbursement codes would allow for lower list prices for the drugs when used in combination for lung cancer, Genentech says.
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.